TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19527591

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 1648

Group type: EXPERIMENTAL
Intervention: Bouts of MVPA
Number of subjects: 1648

Group type: EXPERIMENTAL
Intervention: Demographic characteristics
Number of subjects: 1648

Group type: EXPERIMENTAL
Intervention: Physical activity by day
Number of subjects: 1648

Group type: EXPERIMENTAL
Intervention: Physical activity by time of day
Number of subjects: 1648

Group type: EXPERIMENTAL
Intervention: Physical activity duration
Number of subjects: 1648
Study: 18782843

Group type: EXPERIMENTAL
Intervention: Bear Brand coffee creamer
Number of subjects: 1124
Study: 16045370

Group type: EXPERIMENTAL
Intervention: Medication adherence assessment
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Specific medication-taking behaviors
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Knowledge of blood glucose goals
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Blood pressure and cholesterol medication adherence
Number of subjects: 181
Study: 12390568

Group type: EXPERIMENTAL
Intervention: Polydioxanon (PDS) membrane
Number of subjects: 62

Group type: COMPARATOR
Intervention: Polylactic acid (PLA) matrix barrier
Number of subjects: 62
Study: 10206134

Group type: EXPERIMENTAL
Intervention: Acellular pertussis, diphtheria, tetanus vaccine combined with Haemophilus influenzae type b (Hib) vaccine (PRP‐T)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Whole-cell pertussis, diphtheria, tetanus/PRP‐T vaccine (historical control)
Number of subjects: 262
Study: 7772422

Group type: EXPERIMENTAL
Intervention: Droperidol 20 micrograms kg‐1 i.v. at induction of anaesthesia
Number of subjects: 270
Study: 2347947

Group type: EXPERIMENTAL
Intervention: Veadent (0.03% sanguinarine and 0.2% zinc chloride)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hibident (0.2% chlorhexidine digluconate)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Vehicle solution (control rinse)
Number of subjects: 12
Study: 498714

Group type: EXPERIMENTAL
Intervention: Amantadine 25 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Amantadine 100 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Amantadine 150 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Amantadine (all doses)
Number of subjects: 13
Study: 30280368

Group type: EXPERIMENTAL
Intervention: Total glucosides of peony (TGP) 600 mg, tid for 24 weeks
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Total glucosides of peony (TGP)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study: 29474558

Group type: EXPERIMENTAL
Intervention: Ceritinib 750 mg/day
Number of subjects: 29

Group type: COMPARATOR
Intervention: Chemotherapy (intravenous pemetrexed 500 mg/m2 or docetaxel 75 mg/m2)
Number of subjects: 29
Study: 27486164

Group type: EXPERIMENTAL
Intervention: Average systolic BP ≥160 mm Hg
Number of subjects: 1767

Group type: EXPERIMENTAL
Intervention: Average systolic BP of 120 to 139 mm Hg
Number of subjects: 1767

Group type: EXPERIMENTAL
Intervention: Average systolic BP <120 mm Hg
Number of subjects: 1767

Group type: EXPERIMENTAL
Intervention: Diastolic BP ≥90 mm Hg
Number of subjects: 1767

Group type: EXPERIMENTAL
Intervention: Pulse pressure <50 mm Hg
Number of subjects: 1767

Group type: EXPERIMENTAL
Intervention: Systolic BP ≥160 mm Hg
Number of subjects: 1767

Group type: EXPERIMENTAL
Intervention: BP of 120 to 129 mm Hg
Number of subjects: 1767
Study: 25248448

Group type: EXPERIMENTAL
Intervention: Self-Observation (S-O)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Other-Observation (O-O)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control
Number of subjects: 39
Study: 22321061

Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 131

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 131
Study: 19834744

Group type: EXPERIMENTAL
Intervention: Home-based walking exercise intervention for 8 weeks
Number of subjects: 71

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 71
Study: 17559747

Group type: EXPERIMENTAL
Intervention: DPP-4 inhibitors (sitagliptin, vildagliptin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sulphonylureas, glitazones, basal insulin
Number of subjects: 0
Study: 15951453

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 12047016

Group type: EXPERIMENTAL
Intervention: Cognitive remediation program (3 months)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Leisure group (control condition)
Number of subjects: 42
Study: 12973416

Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7737103

Group type: EXPERIMENTAL
Intervention: Caffeine (150 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg)
Number of subjects: 18
Study: 2292696

Group type: EXPERIMENTAL
Intervention: Vigabatrin (up to 3g daily for eight weeks)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Vigabatrin (during double-blind phase)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (during double-blind phase)
Number of subjects: 33
Study: 7264612

Group type: EXPERIMENTAL
Intervention: HANAflu with 1 microgram (5%) whole virus added
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Commercial vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HANAflu alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HANAflu + 0.2 microgram (1%) whole virus
Number of subjects: 0
Study: 31682327

Group type: EXPERIMENTAL
Intervention: Resilience programming (four-session program including goal-building, mindfulness, and resilience skills)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Resilience programming
Number of subjects: 252

Group type: COMPARATOR
Intervention: Orientation-as-usual (control group)
Number of subjects: 252
Study: 29593782

Group type: EXPERIMENTAL
Intervention: Bilateral tDCS (cathode over C4, anode over C3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study: 27776843

Group type: EXPERIMENTAL
Intervention: FLOT group (docetaxel 50 mg/m2, oxaliplatin 85 mg/m2, leucovorin 200 mg/m2, fluorouracil 2600 mg/m2)
Number of subjects: 300

Group type: COMPARATOR
Intervention: ECF/ECX group (epirubicin 50 mg/m2, cisplatin 60 mg/m2, fluorouracil 200 mg/m2 or capecitabine 1250 mg/m2)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: FLOT group
Number of subjects: 300

Group type: COMPARATOR
Intervention: ECF/ECX group
Number of subjects: 300
Study: 24836086

Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Citalopram
Number of subjects: 0
Study: 22781634

Group type: EXPERIMENTAL
Intervention: Automated oscillometric device (Omron M7)
Number of subjects: 1729

Group type: EXPERIMENTAL
Intervention: Adjustment of automated oscillometric measurements
Number of subjects: 1729
Study: 20820146

Group type: EXPERIMENTAL
Intervention: Pressure Controlled Ventilation (PCV)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sustained Inflation (SI)
Number of subjects: 40
Study: 18269367

Group type: EXPERIMENTAL
Intervention: Happy Ending intervention (internet- and cell-phone-based), lasting 54 weeks with over 400 contacts via e-mail, web-pages, IVR, and SMS
Number of subjects: 396

Group type: COMPARATOR
Intervention: Self-help booklet (control group)
Number of subjects: 396
Study: 16466178

Group type: EXPERIMENTAL
Intervention: Tiaozhi Jiangtang Tablet (TZJT) plus asprin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Asprin alone
Number of subjects: 60
Study: 12834653

Group type: EXPERIMENTAL
Intervention: Spit tobacco (ST) intervention
Number of subjects: 1084

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1084
Study: 10945385

Group type: EXPERIMENTAL
Intervention: Suprasternal Doppler (SST)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Thermodilution (TD)
Number of subjects: 65
Study: 8997686

Group type: EXPERIMENTAL
Intervention: Relaxation response training
Number of subjects: 33

Group type: COMPARATOR
Intervention: Reading (attention-control group)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study: 1464681

Group type: EXPERIMENTAL
Intervention: Traditional internal measurements across the osteotomy lines (15 subjects)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Measurements between the incisor teeth and an external reference point (bone screw at nasion) (30 subjects total, 15 subjects in each group)
Number of subjects: 45
Study: 6509452

Group type: EXPERIMENTAL
Intervention: Chemotherapy alone
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Chemotherapy and radiotherapy
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (patients without secondary leukemia)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: All patients with secondary leukemia
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Time to first sign of preleukemia
Number of subjects: 95
Study: 31524774

Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg tablets plus indomethacin suppository 100 mg
Number of subjects: 411

Group type: COMPARATOR
Intervention: Placebo plus indomethacin suppository 100 mg
Number of subjects: 411
Study: 30306951

Group type: EXPERIMENTAL
Intervention: Basic platform
Number of subjects: 809

Group type: EXPERIMENTAL
Intervention: Enhanced platform
Number of subjects: 809

Group type: COMPARATOR
Intervention: Minimal intervention control group
Number of subjects: 809
Study: 25640652

Group type: EXPERIMENTAL
Intervention: Prayer for romantic partner (self-guided, lasted 3 minutes)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control condition (describing romantic partner's physical attributes)
Number of subjects: 151
Study: 24117862

Group type: EXPERIMENTAL
Intervention: Subcutaneous belimumab 200 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intravenous belimumab 200 mg
Number of subjects: 16
Study: 22084490

Group type: EXPERIMENTAL
Intervention: WBV-full group (n = 20)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: WBV-light group (n = 18)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (n = 17)
Number of subjects: 55
Study: 21179725

Group type: EXPERIMENTAL
Intervention: Xuefu Zhuyu Decoction (XFZYD)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional treatment (Control)
Number of subjects: 120
Study: 18046186

Group type: EXPERIMENTAL
Intervention: Moderate-intensity resistance training program (3 sets of 12 repetitions at 54.9 +/- 2.4% 1RM, 3 times per week for 12 months)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 42
Study: 16127757

Group type: EXPERIMENTAL
Intervention: HCPT d1 and d14 through TAE and portal venous embolization (test group)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Anticancer drugs without HCPT (control I)
Number of subjects: 296

Group type: COMPARATOR
Intervention: HCPT as a major component in anticancer drugs once (control II)
Number of subjects: 296
Study: 12403023

Group type: EXPERIMENTAL
Intervention: Nelfinavir/Zalcitabine/Zidovudine combination
Number of subjects: 40
Study: 10457880

Group type: EXPERIMENTAL
Intervention: Tramadol suppositories 100 mg 6 hourly (qds)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Acetaminophen/codeine suppositories 1000/20 mg qds
Number of subjects: 40
Study: 7847300

Group type: EXPERIMENTAL
Intervention: Continuous infusion of famotidine (20 mg bolus followed by 1.67 mg/h infusion)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intermittent administration of famotidine (20 mg every 12 h)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 2192839

Group type: EXPERIMENTAL
Intervention: Zinc gluconate lozenges (4.5 mg zinc)
Number of subjects: 463

Group type: COMPARATOR
Intervention: Placebo lozenges
Number of subjects: 463
Study: 1021226

Group type: EXPERIMENTAL
Intervention: Tamoxifen (Tam)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tamoxifen (Tam) plus fluoxymesterone (Flu)
Number of subjects: 0
Study: 31451361

Group type: EXPERIMENTAL
Intervention: Self-management education tailored to health literacy
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 118
Study: 31533660

Group type: EXPERIMENTAL
Intervention: HIPEC group (Curative Resection + intraoperative HIPEC with cisplatin 50 mg/m2 at 42.0 ± 1.0 °C for 60 min)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (Curative Resection only)
Number of subjects: 80
Study: 28988646

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenous every 3 weeks
Number of subjects: 86
Study: 25742161

Group type: EXPERIMENTAL
Intervention: Standard Chinese eye exercises group
Number of subjects: 190

Group type: COMPARATOR
Intervention: Sham point eye exercises group
Number of subjects: 190

Group type: COMPARATOR
Intervention: Eyes closed group
Number of subjects: 190
Study: 23505208

Group type: EXPERIMENTAL
Intervention: Adefovir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lamivudine
Number of subjects: 0
Study: 16461865

Group type: EXPERIMENTAL
Intervention: 192 mg of depot naltrexone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 384 mg of depot naltrexone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 15243283

Group type: EXPERIMENTAL
Intervention: Transdermal 17beta-estradiol 50 microg daily plus nomegestrole acetate 5 mg/day for 12 days per 28-day cycle for 6 months (Group A)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intranasal 17beta-estradiol 300 microg/day plus nomegestrole acetate 5 mg/day for 12 days per 28-day cycle for 6 months (Group B)
Number of subjects: 20
Study: 10916105

Group type: EXPERIMENTAL
Intervention: Acetate-free hemodiafiltration with monitoring of blood volume and automatic biofeedback
Number of subjects: 12

Group type: COMPARATOR
Intervention: Acetate-free hemodiafiltration with standard ultrafiltration control
Number of subjects: 12
Study: 8848321

Group type: EXPERIMENTAL
Intervention: External sphincterotomy combined with bladder neck resection
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Bladder neck resection alone
Number of subjects: 125
Study: 1383902

Group type: EXPERIMENTAL
Intervention: COPP
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: ABVD
Number of subjects: 45
Study: 3863444

Group type: EXPERIMENTAL
Intervention: Bite plate with a frontal plateau
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Full‐coverage stabilization splint
Number of subjects: 20
Study: 31832674

Group type: EXPERIMENTAL
Intervention: Testosterone treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31480482

Group type: EXPERIMENTAL
Intervention: Comprehensive intervention
Number of subjects: 1211

Group type: EXPERIMENTAL
Intervention: Top-down intervention (TDI)
Number of subjects: 1211

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1211
Study: 28067613

Group type: EXPERIMENTAL
Intervention: Modified independent cue test
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Conditions promoting output interference
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Conditions controlling output interference
Number of subjects: 6
Study: 26107752

Group type: EXPERIMENTAL
Intervention: Long-acting injectable risperidone
Number of subjects: 86

Group type: COMPARATOR
Intervention: Oral risperidone
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Long-acting risperidone
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Medication adherence
Number of subjects: 86
Study: 23880183

Group type: EXPERIMENTAL
Intervention: ezFMD
Number of subjects: 306
Study: 21699740

Group type: EXPERIMENTAL
Intervention: Collaborative Care Program (CCP)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 32
Study: 20368220

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg, daily)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (20 diabetic patients with atherosclerosis and 14 diabetic patients without atherosclerosis, no statin therapy)
Number of subjects: 23
Study: 17366757

Group type: EXPERIMENTAL
Intervention: Oral hygiene education
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Hand and nail cleaning education
Number of subjects: 61

Group type: COMPARATOR
Intervention: Overall education (both groups)
Number of subjects: 61
Study: 15087990

Group type: EXPERIMENTAL
Intervention: Low pulse frequency stimulus (n = 19)
Number of subjects: 40

Group type: COMPARATOR
Intervention: High pulse frequency stimulus (n = 21)
Number of subjects: 40
Study: 11473862

Group type: EXPERIMENTAL
Intervention: Clonidine 0.2 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Clonidine 0.4 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 9736788

Group type: EXPERIMENTAL
Intervention: Long slow hemodialysis (8 hours, 3 times a week, using 1-1.8 m² cellulosic dialyzers, blood flow 220 ml/min, dialysate flow 500 ml/min, acetate or bicarbonate buffer)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: n-PDUR
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Long slow hemodialysis
Number of subjects: 18
Study: 7988349

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) 1.2 micrograms/kg/day intravenously for four weeks
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Oral methyl vitamin B12 (VB12) 1500 micrograms/day for four weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: No drugs (control group A)
Number of subjects: 38
Study: 2499223

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 30
Study: 31931686

Group type: EXPERIMENTAL
Intervention: PS‐cCBT
Number of subjects: 330

Group type: COMPARATOR
Intervention: Usual-care control
Number of subjects: 330
Study: 30908880

Group type: EXPERIMENTAL
Intervention: Shaft of the radius (diaphysis)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Proximal metaphysis
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Distal metaphysis
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Diaphysis
Number of subjects: 3
Study: 28580894

Group type: EXPERIMENTAL
Intervention: MRSA guidelines implemented in adult teaching facilities (2007-2009)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MRSA guidelines and interventions (2010-2015)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CLABSI incidence (2006-2007)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CLABSI incidence (2010-2015)
Number of subjects: 0
Study: 26305004

Group type: EXPERIMENTAL
Intervention: Patient history and clinical examination
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Patient history, clinical examination, and MRI findings
Number of subjects: 180
Study: 22643242

Group type: EXPERIMENTAL
Intervention: High-protein condition (PROT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High-carbohydrate condition (CARB)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 30
Study: 21729308

Group type: EXPERIMENTAL
Intervention: Intravenous hypotonic solution (0.23% or 0.40% sodium chloride in glucose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous near-isotonic solution (0.81% sodium chloride in glucose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both interventions (hypotonic and near-isotonic)
Number of subjects: 0
Study: 19467416

Group type: EXPERIMENTAL
Intervention: Modified UPPP
Number of subjects: 32

Group type: COMPARATOR
Intervention: Classic UPPP
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study: 16132994

Group type: EXPERIMENTAL
Intervention: Phacoemulsification and IOL implantation in eyes with angle-closure glaucoma
Number of subjects: 24

Group type: COMPARATOR
Intervention: Partner eyes with narrow angle and iridectomy or iridotomy
Number of subjects: 24
Study: 15283928

Group type: EXPERIMENTAL
Intervention: Resistance training (3 times a week for 12 weeks) with HRT
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Resistance training (3 times a week for 12 weeks) with NHRT
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Resistance training (3 times a week for 12 weeks)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no resistance training) with HRT
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no resistance training) with NHRT
Number of subjects: 32
Study: 11196741

Group type: EXPERIMENTAL
Intervention: New measles-mumps-rubella (MMR) vaccine (Priorix, SmithKline Beecham)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Commercially available MMR vaccine (MMR-II, Merck)
Number of subjects: 44
Study: 9031821

Group type: EXPERIMENTAL
Intervention: Lofexidine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 28
Study: 7687948

Group type: EXPERIMENTAL
Intervention: Educational and family support services and pediatric follow‐up
Number of subjects: 985

Group type: COMPARATOR
Intervention: Follow-up group (control)
Number of subjects: 985
Study: 2872514

Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 150

Group type: COMPARATOR
Intervention: Tonsillectomy
Number of subjects: 150

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 150
Study: 30566712

Group type: EXPERIMENTAL
Intervention: Intraoperative PFC injection
Number of subjects: 30

Group type: COMPARATOR
Intervention: No PFC injection (Control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Patients with metamorphopsia
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Preoperative macula-off RRD
Number of subjects: 30
Study: 27491822

Group type: EXPERIMENTAL
Intervention: Measurement of the blood level of the biomarker soluble urokinase plasminogen activator receptor (suPAR) within 2 hours after admission, with immediate reporting to treating physicians in the ED.
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Education of all ED physicians in the prognostic capabilities of suPAR prior to the inclusion period.
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Availability of prognostic information from suPAR.
Number of subjects: 10000
Study: 24884415

Group type: EXPERIMENTAL
Intervention: Women indicating that they had been in labour for 24 hours or longer at the time of hospital admission
Number of subjects: 1247
Study: 22258294

Group type: EXPERIMENTAL
Intervention: Standardized 45 min relaxation session with a health psychologist and relaxation exercise CDs
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60